Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance data.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs. On February 12, 2009, an increase in the notional allocation of Ordinary Share ADRs occurred at a price of $35.33 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on February 12, 2009.
- Share Price: The transaction price was $35.33 per ADR.
- Involved Parties: The notification covers Dr. M M Slaoui (5 ADRs), Mrs. C Bruck Slaoui (1 ADR), Mr. E J Gray (23 ADRs), Mr. W C Louv (11 ADRs), and Dr. D Pulman (24 ADRs).
- Plan Context: These transactions relate to the US Retirement Savings Plan and are not direct market purchases by the individuals.